Compare Stocks → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATOSNASDAQ:ESPRNASDAQ:FBRXNASDAQ:GERNNASDAQ:PRVB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Therapeutics$1.42+3.6%$1.40$0.59▼$2.31$171.67M1.192.95 million shs1.02 million shsESPREsperion Therapeutics$1.91-2.1%$2.45$0.70▼$3.40$369.33M0.849.41 million shs4.79 million shsFBRXForte Biosciences$0.72-1.4%$0.70$0.38▼$1.15$26.71M0.4826,932 shs16,031 shsGERNGeron$3.73+1.1%$2.77$1.64▼$4.05$2.02B0.6110.11 million shs8.21 million shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Therapeutics+3.65%-16.96%-14.97%+72.50%+102.86%ESPREsperion Therapeutics-2.05%-1.29%-16.59%-10.33%+49.22%FBRXForte Biosciences-1.91%+1.41%+2.80%+4.35%-32.71%GERNGeron+1.08%+8.12%+12.69%+75.12%+39.70%PRVBProvention Bio0.00%0.00%0.00%0.00%+2.71%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Therapeutics1.1778 of 5 stars3.51.00.00.02.31.70.0ESPREsperion Therapeutics3.6905 of 5 stars3.22.00.03.93.50.80.6FBRXForte Biosciences3.2766 of 5 stars3.35.00.00.02.22.51.3GERNGeron2.9029 of 5 stars3.53.00.01.30.01.70.6PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Therapeutics3.00Buy$4.50216.90% UpsideESPREsperion Therapeutics2.40Hold$9.33388.66% UpsideFBRXForte Biosciences2.50Moderate Buy$2.75281.94% UpsideGERNGeron3.00Buy$5.3342.98% UpsidePRVBProvention BioN/AN/AN/AN/ACurrent Analyst RatingsLatest FBRX, PRVB, GERN, ATOS, and ESPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/11/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/10/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.004/8/2024FBRXForte BiosciencesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.754/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/25/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/25/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/15/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/AESPREsperion Therapeutics$116.33M3.11N/AN/A($3.85) per share-0.50FBRXForte BiosciencesN/AN/AN/AN/A$0.97 per shareN/AGERNGeron$240K8,499.27N/AN/A$0.46 per share8.11PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)ESPREsperion Therapeutics-$209.25M-$2.12N/A6.16N/A-179.87%N/A-91.62%5/14/2024 (Estimated)FBRXForte Biosciences-$31.48M-$1.04N/AN/AN/AN/A-94.27%-81.36%5/20/2024 (Estimated)GERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ALatest FBRX, PRVB, GERN, ATOS, and ESPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/A3/18/2024Q4 2023FBRXForte BiosciencesN/A-$0.04-$0.04-$0.04N/AN/A2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million 2/27/202412/31/2023ESPREsperion Therapeutics-$0.53-$0.50+$0.03-$0.50$26.84 million$32.25 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa TherapeuticsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa TherapeuticsN/A17.6117.61ESPREsperion TherapeuticsN/A1.290.87FBRXForte BiosciencesN/A10.4510.45GERNGeron0.143.163.16PRVBProvention Bio0.191.931.92OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Therapeutics12.74%ESPREsperion Therapeutics47.39%FBRXForte Biosciences77.63%GERNGeron73.71%PRVBProvention Bio37.39%Insider OwnershipCompanyInsider OwnershipATOSAtossa Therapeutics7.80%ESPREsperion Therapeutics1.00%FBRXForte Biosciences10.53%GERNGeron3.00%PRVBProvention Bio13.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Therapeutics12125.30 million115.53 millionOptionableESPREsperion Therapeutics240189.40 million187.51 millionOptionableFBRXForte Biosciences936.40 million32.56 millionOptionableGERNGeron141546.87 million530.47 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableFBRX, PRVB, GERN, ATOS, and ESPR HeadlinesSourceHeadlineMacrogenics Inc MGNXmorningstar.com - December 29 at 11:00 PMAnd for Wegovy's Next Trick, Full-Blown Cardiovascular Benefit Outside Diabetesmedpagetoday.com - November 13 at 5:48 PMTeplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetesnejm.org - October 24 at 9:51 AMFDA sets August decision date for Provention's type 1 diabetes drugpharmaphorum.com - July 23 at 5:52 PMLarry Pine Biography & Moviestribute.ca - June 27 at 3:22 PMSanofi/Provention: innovative diabetes drug is a good fitfinance.yahoo.com - May 1 at 10:47 AMThose who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%finance.yahoo.com - April 29 at 9:55 AMSanofi completes Provention Bio acquisitionseekingalpha.com - April 28 at 9:22 AMSanofi concludes acquisition of Provention Biomedicaldialogues.in - April 28 at 4:06 AMSanofi completes acquisition of Provention Bio, Inc.pharmiweb.com - April 28 at 4:06 AMEarnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Declinefinance.yahoo.com - April 27 at 1:01 PMSanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.finanznachrichten.de - April 27 at 2:00 AMProvention Bio gains after HSR waiting period for Sanofi deal expiredseekingalpha.com - April 26 at 3:59 PMPress Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.benzinga.com - April 26 at 10:51 AMSanofi’s $2.9 Billion Provention Bio Deal Draws Investor Lawsuitnews.bloomberglaw.com - April 25 at 11:24 PMPRVB Apr 2023 23.000 putfinance.yahoo.com - April 22 at 10:13 AMSanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Informationmsn.com - April 11 at 3:59 PMProvention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their Estimatesfinance.yahoo.com - April 2 at 10:41 AMGaithersburg’s Novavax locks in consulting deal with outgoing R&D headbizjournals.com - March 27 at 7:11 PM(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?benzinga.com - March 17 at 7:02 PMQ4 2022 MacroGenics Inc Earnings Callfinance.yahoo.com - March 16 at 9:12 AMProvention Bio's Earnings Outlookbenzinga.com - March 15 at 2:10 PMSMBC Nikko Downgrades Provention Bio (PRVB)msn.com - March 14 at 10:52 PMJefferies Downgrades Provention Bio (PRVB)msn.com - March 14 at 10:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Esperion TherapeuticsNASDAQ:ESPREsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Forte BiosciencesNASDAQ:FBRXForte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.GeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.